Constitutional de novo t(1;22)(p22;q11.2) and ependymoma

Cancer Genetics and Cytogenetics
J P ParkC H Rhodes

Abstract

There is a body of evidence suggesting the presence of a tumor suppressor gene on chromosome 22 which plays a role in the pathogenesis of ependymomas. We report a patient with a de novo constitutional t(1;22)(p22;q11.2) who developed a malignant ependymoma at age 5. The patient is otherwise phenotypically normal. By fluorescence in situ hybridization (FISH) analysis, the chromosome 22 breakpoint has been localized to the region between the DiGeorge locus and BCR. Since NF2 and EWS are both distal to BCR, the are presumable not involved in this rearrangement. This patient may offer a unique opportunity to identify the chromosome 22 ependymoma tumor suppressor gene by cloning the translocation breakpoint.

References

Jul 1, 1992·Pediatric Hematology and Oncology·A M Vagner-CapodanoC Raybaud
Feb 1, 1992·Cancer Genetics and Cytogenetics·G ThielR Witkowski
May 1, 1992·Cancer Genetics and Cytogenetics·C A GriffinH Brem
Jul 15, 1992·Cancer Genetics and Cytogenetics·S WeremowiczJ A Fletcher
Feb 1, 1995·Cancer Genetics and Cytogenetics·C WernickeR Witkowski
Oct 1, 1994·Journal of Neurology, Neurosurgery, and Psychiatry·P C NijssenM F Niermeyer
Sep 1, 1993·Cancer Genetics and Cytogenetics·S R RogattoJ Barbieri-Neto

❮ Previous
Next ❯

Citations

Nov 7, 2000·Cancer Genetics and Cytogenetics·M Rousseau-MerckA M Vagner-Capodano
May 9, 2002·Cancer Genetics and Cytogenetics·M Eva AlonsoJuan A Rey
Mar 28, 2003·Cancer Genetics and Cytogenetics·Jeffrey R SawyerMark E Linskey
Aug 5, 1998·Cancer Genetics and Cytogenetics·S SavaşanE Abella
Aug 25, 1999·Cancer Genetics and Cytogenetics·C MazewskiB Lampkin
Dec 22, 1999·Cancer Genetics and Cytogenetics·A M Vagner-CapodanoM Choux
Nov 14, 2003·Human Molecular Genetics·Anthony L GotterBeverly S Emanuel
Apr 1, 1997·Brain Pathology·R L Hamilton, I F Pollack
Aug 2, 2006·Cytopathology : Official Journal of the British Society for Clinical Cytology·D TamiolakisC Simopoulos
Mar 18, 2004·Neurosurgery Clinics of North America·James S Waldron, Tarik Tihan
Dec 9, 1998·Cancer Investigation·G L Applegate, M H Marymont
Dec 10, 1999·British Journal of Cancer·T J HulsebosC C Tijssen
Feb 26, 2019·Cytogenetic and Genome Research·Spiros VittasVasiliki Soubasi
Jan 4, 1998·Journal of Pediatric Hematology/oncology·J A Biegel
Apr 2, 2005·Journal of Neuro-oncology·Mariarita SantiElisabeth J Rushing

❮ Previous
Next ❯

Related Concepts

Related Feeds

22q11 Deletion Syndrome

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a congenital disorder caused by a partial deletion of chromosome 22. Symptoms include heart defects, poor immune system function, a cleft palate, complications related to low levels of calcium in the blood, and delayed development. Discover the latest research on this disease here.

Related Papers

Cancer Genetics and Cytogenetics
C WernickeR Witkowski
Cancer Genetics and Cytogenetics
J R SawyerW M Chadduck
Cancer Genetics and Cytogenetics
S R RogattoJ Barbieri-Neto
Journal of Neurology, Neurosurgery, and Psychiatry
P C NijssenM F Niermeyer
© 2021 Meta ULC. All rights reserved